NCT03926390

Brief Summary

The aim was to assess the ability of bovine colostrum concentrate to reduce the incidence of late-onset sepsis episodes and necrotizing enterocolitis in artificially fed preterm neonates and its effect on T regulatory cells. And to evaluate the effect of bovine colostrum concentrate on feeding tolerance, growth, hospital stay and mortality in preterm neonates.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 15, 2018

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 8, 2018

Completed
6 months until next milestone

First Posted

Study publicly available on registry

April 24, 2019

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2019

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2019

Completed
Last Updated

June 23, 2020

Status Verified

June 1, 2020

Enrollment Period

9 months

First QC Date

November 8, 2018

Last Update Submit

June 21, 2020

Conditions

Outcome Measures

Primary Outcomes (3)

  • Incidence of Late Onset Sepsis in the three groups

    Incidence of Late Onset Sepsis in the studied group measured by rodwell and tollner sepsis scoring system

    From time of randomization to discharge from nicu or death whichever comes first

  • The incidence of Necrotizing Enterocolitis in the three groups

    Incidence of Necrotizing Enterocolitis in the three groups diagnosed according to bell's staging

    From time of randomization to discharge from nicu or death whichever comes first

  • The change of Active T regulatory cells In the three groups

    Active T regulatory cells diagnosed by cell CD 4 expressing CD 25 high or simultaneously CD 25 plus FOXP3

    Change from base line at randomization and after intervention by 1 week

Secondary Outcomes (3)

  • Feeding intolerance is defined as presence of at least 3 consecutive days of any of the following:emesis, gastric residuals, diarrhea, blood in stools or abnormally enlarged bowel loops

    From time of randomization to discharge from nicu or death whichever comes first

  • Neonatal mortality

    From time of randomization to discharge from nicu or death whichever comes first

  • Duration of hospital stay

    From time of randomization to discharge from nicu or death whichever comes first

Study Arms (2)

Non bovine colostrun

NO INTERVENTION

Preterm received preterm formula

Bovine colostrum group

ACTIVE COMPARATOR

Preterm received bovine colostrum as trophic feeding

Dietary Supplement: Bovine colostrum

Interventions

Bovine colostrumDIETARY_SUPPLEMENT

bovine colostrum for first 2 weeks

Bovine colostrum group

Eligibility Criteria

Age24 Hours - 28 Days
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Preterm Neonate having a gestational age equal or less than 34 weeks at birth, admitted in Ain-Shams University NICUs

You may not qualify if:

  • Maternal risk factor of early onset sepsis, chorioamnionitis.
  • Proved early onset sepsis.
  • Life-threatening congenital abnormalities.
  • Inborn error of metabolism.
  • Chromosomal aberrations.
  • Neonates with underlying gastrointestinal problems (such as GIT anomalies) that prevent enteral feeding.
  • Perinatal asphyxia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medicin

Giza, Abasseya, 05000, Egypt

Location

MeSH Terms

Conditions

Neonatal Sepsis

Condition Hierarchy (Ancestors)

SepsisInfectionsInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Hisham Awad

    professor of pediatrics Ain Shams university

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical professor

Study Record Dates

First Submitted

November 8, 2018

First Posted

April 24, 2019

Study Start

September 15, 2018

Primary Completion

June 15, 2019

Study Completion

September 15, 2019

Last Updated

June 23, 2020

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will not share

research protocol

Locations